Life Science Today

Life Science Today 061 – Bonus Episode – Interview with Brazen Bio founders Shawn Carbonell and Brent Witgen

July 30, 2021 Noah Goodson, PhD Season 2 Episode 61
Life Science Today 061 – Bonus Episode – Interview with Brazen Bio founders Shawn Carbonell and Brent Witgen
Life Science Today
More Info
Life Science Today
Life Science Today 061 – Bonus Episode – Interview with Brazen Bio founders Shawn Carbonell and Brent Witgen
Jul 30, 2021 Season 2 Episode 61
Noah Goodson, PhD

Originally Published as The Niche Podcast

In this special bonus episode, Dr. Noah Goodson sits down with biotech founders Dr. Shawn Carbonell and Dr. Brent Witgen to discuss their new founder-friendly biotech incubator Brazen Bio.

Find out more at
https://thenichepod.com

Story References
https://wefunder.com/brazenbio/
https://www.linkedin.com/company/brazenbio/
https://www.brazen.bio

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson


Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Show Notes Transcript

Originally Published as The Niche Podcast

In this special bonus episode, Dr. Noah Goodson sits down with biotech founders Dr. Shawn Carbonell and Dr. Brent Witgen to discuss their new founder-friendly biotech incubator Brazen Bio.

Find out more at
https://thenichepod.com

Story References
https://wefunder.com/brazenbio/
https://www.linkedin.com/company/brazenbio/
https://www.brazen.bio

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson


Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Introduction

Welcome to The Niche Podcast – Your weekly rundown of the biotech, pharma, clinical research, and life science industries. I’m your host, Dr. Noah Goodson. In this special bonus episode, I sit down with biotech founders Dr. Shawn Carbonell and Dr. Brent Wigen to discuss their new founder-friendly biotech incubator Brazen Bio.

Disclaimer

The views expressed on The Niche Podcast are those of the host and guests. They do not necessarily reflect the opinions of any organizations or companies with which they are affiliated.

Introduction

Welcome to a monthly bonus episode. Today I’m talking to a pair of startup founders who are trying to help other biotech startup founders.

Shawn Carbonell, MD, PhD quit his neurosurgery residency to found his first biotech startup a decade ago. He invented and developed a first-in-class cancer drug which is currently in phase 1 clinical trial.

Brent Witgen, PhD had been in big pharma for the past decade, with direct involvement in over a dozen drug and device regulatory filings across multiple areas of human disease. He has built high-performing biotech teams in the US, EU, and Asia.

Together they have recently launched Brazen Bio to help biotech founders advance human health. Brazen Bio is building a turnkey incubator program with state-of-the-art laboratory access, including specialized equipment, technical support, expert advisors and accommodation. Based in LA they are planning to run the first cohort of founders through the program.

So what does that mean practically? Well, it’s a chance for graduate students, post-docs, and early career scientists to try and turn their idea into an actual business.

I want to be really clear here. I have no idea if this will work or not. I do not have any money invested in Brazen Bio and I would not personally recommend for or against them. What I can say, is they are trying to do something a little different, which is take the incubator idea from tech and apply it to biotech.

In the biotech industry, most innovations are actually technological or scientific advancements. I would distinguish this from innovation which implies a new approach or way of thinking. Brazen is at least attempting to innovate. Time will tell if this model is successful. But I think it’s worth hearing their story and vision. Enjoy.

*Rest of Transcript Unavailable*

Closing Thoughts

I hope you enjoyed this bonus episode. You can find out more about Brazen Bio by visiting brazen.bio, or get onboard as an early investor at wefunder.com/brazenbio. We’ll be back on Monday with more top news and stories. 

Closing Credits

Thanks for joining me on The Niche Podcast; your weekly summary of top news in the biotech, pharma clinical research, and life science industries. You can learn more at thenichepod.com or find us on your favorite podcast app. Like, comment, subscribe, and most of all share with your friends. If you like what you hear, please rate and review, it really helps us. Once again, I’m Dr. Noah Goodson, I’ll see you next week. 

Show Notes

In this special bonus episode, Dr. Noah Goodson sits down with biotech founders Dr. Shawn Carbonell and Dr. Brent Witgen to discuss their new founder-friendly biotech incubator Brazen Bio.


About the Show

The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.